arrow
T

Tatsuya Nakatani

Nara Medical University
H指数:51
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-Term Effects of Nalmefene on Alcohol Consumption, Liver Function, and Gut Microbiota in Patients With Alcohol-Related Liver Disease

纳美芬对酒精相关肝病患者酒精摄入、肝功能及肠道微生物群的长期影响

2026-09-070
PRE
Correction: Nishimura et al. Rifaximin Attenuates Liver Fibrosis and Hepatocarcinogenesis in a Rat MASH Model by Suppressing the Gut–Liver Axis and Epiregulin–IL-8-Associated Angiogenesis. Int. J. Mol. Sci. 2025, 26, 6710

更正:Nishimura等人。利福昔明通过抑制肠-肝轴和表皮调节素-IL-8相关的血管生成,在一种大鼠MASH模型中减轻肝纤维化和肝细胞癌发生。Int. J. Mol. Sci. 2025, 26, 6710

2026-08-140
OA
Dual therapy with vildagliptin and sacubitril/valsartan alleviates portal hypertension and inhibits soluble epoxide hydrolase in cirrhotic rats

维格列汀和沙库巴曲/缬沙坦双重疗法可缓解肝硬化大鼠的门静脉高压并抑制可溶性环氧酶水解酶。

2025-09-070
OA
Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism A Randomized Clinical Trial
2021-03-0822
OA
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

比卡鲁胺联合雄激素阻断治疗去势抵抗性前列腺癌的恩扎鲁胺与氟他胺: 多中心随机II期试验的研究方案 (ocuu-crpc研究)

2019-04-1115
OAAI
Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis The J-DAVID Randomized Clinical Trial
2018-12-1155
OAAI